Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Link opens in a new tab
Search content at Tel Aviv University
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Clinical Features and Outcome of Primary Pancreatic Lymphoma
Eran Sadot
, Joachim Yahalom
, Richard Kinh Gian Do
, Julie Teruya-Feldstein
, Peter J. Allen
, Mithat Gönen
, Michael I. D’Angelica
, T. Peter Kingham
, William R. Jarnagin
, Ronald P. DeMatteo
*
*
Corresponding author for this work
Memorial Sloan-Kettering Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
40
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Clinical Features and Outcome of Primary Pancreatic Lymphoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Clinical Outcomes
100%
Clinical Features
100%
Primary Pancreatic Lymphoma
100%
Disease-specific Survival
60%
Histological Subtypes
40%
International Prognostic Index
40%
Complete Response Rate
40%
Chemotherapy
20%
Low Risk
20%
Well-defined
20%
Clinical Data
20%
Lymphoma
20%
Favorable Outcome
20%
Resection
20%
Initial Treatment
20%
Non-Hodgkin Lymphoma
20%
Renal Vein
20%
Systemic Therapy
20%
Palliation
20%
Kaplan-Meier
20%
Chart Review
20%
Low-risk Patients
20%
Lymphadenopathy
20%
Distant Site
20%
Log-rank Test
20%
Imaging Characteristics
20%
Pancreatic Tumor
20%
Rare Tumors
20%
Unresectable Tumor
20%
Median Overall Survival
20%
Chemotherapy Alone
20%
Curative Intent
20%
Surgery Alone
20%
Institutional Experience
20%
Optimal Therapy
20%
Carbohydrate Antigen 19-9 (CA19-9)
20%
Institutional Database
20%
Survival Distribution
20%
Non-curative
20%
Medicine and Dentistry
Clinical Feature
100%
Disease Specific Survival
100%
International Prognostic Index
66%
Chemotherapy
66%
Symptomatic Treatment
33%
Non-Hodgkin Lymphoma
33%
Lymphadenopathy
33%
Overall Survival
33%
Systemic Therapy
33%
Lactate Dehydrogenase
33%
Tumor
33%
Pancreas Tumor
33%
Rare Tumor
33%
Log Rank Test
33%
Carcinoembryonic Antigen
33%
Renal Vein
33%